Risk of lymphoid neoplasia after cardiothoracic transplantation. A cohort study of the relation to Epstein-Barr virus

Transplantation

Volumn 69, Issue 5, 2000, Pages 897-904

  Swerdlow, Anthony J ^a   Higgins, Craig D ^a   Hunt, Beverley J ^b   Thomas, J Alero ^a   Burke, Margaret M ^c   Crawford, Dorothy H ^a   Yacoub, Magdi H ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS RNA;

ADOLESCENT; ADULT; AGE; ANTIBODY TITER; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHILD; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HEART LUNG TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; ORGAN DONOR; PRIORITY JOURNAL; RISK ASSESSMENT; VIRUS CARCINOGENESIS;

EID: 0034654097     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200003150-00039     Document Type: Article

References (37)

1. Krikorian JG, Anderson JL, Bieber CP, Penn I, Stinson EB. Malignant neoplasms following cardiac transplantation. J Am Med Assoc 1978; 240: 639.
2. Anderson JL, Fowles RE, Bieber CP, Stinson EB. Idiopathic cardiomyopathy, age, and suppressor-cell dysfunction as risk determinants of lymphoma after cardiac transplantation. Lancet 1978; 2: 1174.
3. Starzl TE. Discussion of 'Five years' experience in renal transplantation with immunosuppressive drugs'. Ann Surg 1968; 168: 416.
4. Perm I, Cancers complicating organ transplantation. N Engl J Med 1990; 323: 1767.
5. Hoover R, Fraumeni JF Jr. Risk of cancer in renal-transplant recipients. Lancet 1973; 2: 55.
6. Hoover R. Effects of drugs - immunosuppression. In: Hiatt HH, Watson JD, Winsten JA, eds. Origins of human cancer. Book A. Incidence of cancer in humans. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1977: 369.
7. Kinlen LJ, Sheil AGR, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979; 2: 1461.
8. Thomas JA, Allday MJ, Crawford DH. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv Cancer Res 1991; 57: 329.
9. Sokal EM, Caragiozoglou T, Lamy M, Reding R, Otte JB. Epstein-Barr virus serology and Epstein-Barr virus-associated lymphoproliferative disorders in pediatric liver transplant recipients. Transplantation 1993; 56: 1394.
10. Thomas JA, Hotchin NA. Allday MJ, et al. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 1990; 49: 944.
11. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152: 876.
12. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719.
13. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877.
14. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 1991; 23: 1473.
15. Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64: 1438.
16. Boyle GJ, Michaels MG, Webber SA, et al. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997; 131: 309.
17. Opelz G, Henderson R, for the Collaborative Transplant Study. Incidence of non-Hodgkin's lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514.
18. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995; 60: 183.
19. Hoshida Y, Tsukuma H, Yasunaga Y, et al. Cancer risk after renal transplantation in Japan. Int J Cancer 1997; 71: 517.
20. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723.
21. Haque T, Thomas JA, Falk KI, et al. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 1996; 77: 1169.
22. Henle G, Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol 1966; 91: 1248.
23. Guohua P, Yi Z, Winping Z, Qin Z. Development of an anticomplement immunoenzyme test for detection of EB virus nuclear antigen (EBNA) and antibody to EBNA. J Immunol Methods 1981; 44: 73.
24. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14: 8.
25. Swerdlow SH. Post-transplant lymphoproliferative disorders: a working classification. Curr Diagn Pathol 1997; 4: 28.
26. Harris NL, Jaffe ES, Stein H, et al. A Revised European-American Classification of Lymphoid Neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361.
27. Clayton D, Hills M. Statistical models in epidemiology. Oxford: Oxford University Press, 1993.
28. Crawford DH. Epstein-Barr virus. In: Zuckerman AJ, Banatvala JE, Pattison JR, eds. Principles and practice of clinical virology. 3rd Ed. Chichester: Wiley, 1994.
29. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmon RL. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461.
30. Thestrup-Pedersen K, Esmann V, Bisballe S, et al. Epstein-Barr-virus-induced lymphoproliferative disorder converting to fatal Burkitt-like lymphoma in a boy with interferon-inducible chromosomal defect. Lancet 1980; 2: 997.
31. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583.
32. Cen H, Breinig MC, Atchison RW, Ho M, McKnight JLC. Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3 and IR4. J Virol 65: 976.
33. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Transplantation 1993; 56: 88.
34. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantation. J Heart Lung Transplant 1995; 14: 214.
35. Weintraub J, Wamke RA. Lymphoma in cardiac allotransplant recipients: clinical and histological features and immunological phenotype. Transplantation 1982; 33: 347.
36. Hoover RN. Lymphoma risks in populations with altered immunity: a search for mechanism. Cancer Res 1992; 52 (suppl): 5477s.
37. Brooks L, Thomas JA. The significance of Epstein Barr virus in the pathogenesis of lymphoid and epithelial neoplasia. Curr Diagn Pathol 1995; 2: 163.